Trials / Completed
CompletedNCT02777671
Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Bial - Portela C S.A. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
Single centre, randomised, open-label, two-way crossover study to investigate whether multiple-dose administration of eslicarbazepine acetate (ESL, BIA 2-093) affects the pharmacokinetics of gliclazide.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BIA 2-093 | |
| DRUG | Gliclazide | tablets containing gliclazide 80 mg (Diamicron® 80 mg) |
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2007-12-01
- Completion
- 2007-12-01
- First posted
- 2016-05-19
- Last updated
- 2016-05-19
Locations
1 site across 1 country: Portugal
Source: ClinicalTrials.gov record NCT02777671. Inclusion in this directory is not an endorsement.